F-star Therapeutics (NASDAQ:FSTX) Lowered to Market Perform at William Blair

William Blair cut shares of F-star Therapeutics (NASDAQ:FSTXGet Rating) from an outperform rating to a market perform rating in a research note issued to investors on Thursday morning, The Fly reports.

Separately, HC Wainwright initiated coverage on shares of F-star Therapeutics in a report on Tuesday, May 17th. They issued a buy rating and a $35.00 target price for the company. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of Hold and an average price target of $29.50.

NASDAQ:FSTX opened at $6.36 on Thursday. The company has a 50-day moving average price of $3.04 and a 200-day moving average price of $3.64. F-star Therapeutics has a 12 month low of $2.07 and a 12 month high of $9.38. The company has a current ratio of 6.11, a quick ratio of 6.11 and a debt-to-equity ratio of 0.14. The stock has a market cap of $137.11 million, a price-to-earnings ratio of -4.13 and a beta of 1.84.

F-star Therapeutics (NASDAQ:FSTXGet Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.06. The company had revenue of $2.55 million during the quarter, compared to analysts’ expectations of $2.30 million. Equities analysts forecast that F-star Therapeutics will post -2.35 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its stake in shares of F-star Therapeutics by 1.6% in the first quarter. BlackRock Inc. now owns 295,947 shares of the company’s stock worth $1,050,000 after acquiring an additional 4,776 shares during the period. State Street Corp grew its stake in shares of F-star Therapeutics by 15.6% in the first quarter. State Street Corp now owns 53,150 shares of the company’s stock worth $189,000 after acquiring an additional 7,180 shares during the period. JPMorgan Chase & Co. grew its stake in shares of F-star Therapeutics by 152.7% in the first quarter. JPMorgan Chase & Co. now owns 21,335 shares of the company’s stock worth $76,000 after acquiring an additional 12,891 shares during the period. Envestnet Asset Management Inc. bought a new stake in shares of F-star Therapeutics in the first quarter worth approximately $48,000. Finally, Geode Capital Management LLC grew its stake in shares of F-star Therapeutics by 11.6% in the third quarter. Geode Capital Management LLC now owns 145,431 shares of the company’s stock worth $1,064,000 after acquiring an additional 15,152 shares during the period. Hedge funds and other institutional investors own 51.67% of the company’s stock.

About F-star Therapeutics (Get Rating)

F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

Read More

The Fly logo

Analyst Recommendations for F-star Therapeutics (NASDAQ:FSTX)

Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.